The present disclosure relates to drug administration. In an exemplary embodiment, a system can include a drug administration device configured to dispense a drug to a patient, a monitoring device configured to log a delivery event of drug delivery from the drug administration device into the patient, and a sensor configured to sense a patient parameter following delivery of the drug into the patient. In another exemplary embodiment, a drug administration device can include a drug holder configured to hold a drug, a dispensing mechanism configured to dispense the drug, and a sensor configured to sense a patient parameter, and the drug administration device can be configured to locally activate the drug at a target location in the patient. In another exemplary embodiment, methods, devices, and systems are provided to assess when operation of a drug dispensing mechanism is complete and to confirm whether drug administration was successful.

The invention relates to an inhaler, particularly an electronic cigarette product, comprising at least one evaporator device having at least one electrical evaporator for evaporating liquid supplied to the evaporator and an electronic control device for controlling and/or regulating the evaporator. A plurality of liquids are associated or can be associated with the evaporator device in such a way that the composition and/or the vapour production rate of the vapour/aerosol produced by the at least one evaporator can be adjusted and/or modified in a targeted manner, as the control device is designed for individual control of the at least one or each individual evaporator and/or for group control of the evaporators.

Methods and apparatuses for the therapeutic delivery of nicotine for smoking cessation, harm reduction and/or substitution. Furthermore, the devices and methods herein are useful as an alternative, general nicotine delivery system in place of tobacco combustion or high temperature (over 150 degrees C.) products. In addition, the methods and devices herein are useful for the therapeutic delivery of a drug, for reducing the cumulative drug dose and hence its potential toxic side effects, while increasing its neurophysiological and/or physiological effects. Moreover, the devices and methods herein are useful for addiction treatment or reduction. In certain embodiments, the methods are adaptable to a medicament delivery device that determines a sequence of drug doses to be delivered. Dose information may be used to control operation of the device.

Methods and compositions for treating mTBI, PTSD or mTBI with PTSD with psychedelic agents and N-acetylcysteine are provided. Nasal mist transducers for administration of one or more pharmaceutically active ingredients such as these as fine mist particles at preselected dosages and times are also provided.

Aspects and embodiments of the present invention generally include a device for patient self-administration of a prescribed medication. The device makes available for administration the precise quantity of medication constituting a dose at times designated by a health care provider (HCP). Preferably, the device also detects and transmits information to a remote management system accessible to the HCP, including detected attempts to tamper with the device. Advantageously, HCPs may render oversight and control over the device and its use to mitigate risks associated with patients self-administering medication without in-person supervision. This control may include establishing prerequisites the patient must meet prior to a dose being made available, or remote deactivation of the device. This oversight by the HCP may include patient-specific and aggregate data analysis for optimization of treatment or evaluation of the safety and efficacy of a treatment. Furthermore, this oversight may be conducted via a web-based interface.

Systems and methods are provided for generating and applying biomimicry tear film layers to a cornea surface. An example method includes forming a multiple layered tear film that are optically transparent, ultra-thin, and smoothly conforming to cornea surface. The multiple layered tear film can include a biomimicry adhesive layer, a biomimicry aqueous layer, and a biomimicry lipid layer. An atomizer/nebulizer/micronizer can be used to generate and applying the biomimicry tear film layers.

The present invention relates to the use of human anti-inflammatory peptides in the inhalatory treatment of inflammatory pulmonary diseases. The invention in particular relates to the use of vasoactive intestinal peptide, C-type natriuretic peptide, B-type natriuretic peptide, pituitary adenylate cyclase-activating peptide, adrenomedullin, alpha-melanocyte stimulating hormone, relaxin and Interferon gamma for said purposes. Advantageous features of an aerosol containing such a human anti-inflammatory peptide and a method for producing said aerosol are disclosed. The present invention further relates to a kit for inhalatory treatment of inflammatory pulmonary diseases. One aspect relates to treatment of CoViD-19 related ARDS.

Systems and methods are provided for aerosolizing and delivering therapeutic substances in an electronic aerosol delivery device with airflow regulation. Calibrated airflow resistance settings enable adjustment and control of flow velocity and or flow volume of air, aerosolized air, and or entrained aerosol particles, through the device, for optimal aerosol delivery among diverse conditions and applications.

Systems and methods for fluid delivery into a ventilation system are disclosed. In an example, the technology relates to a fluid delivery system for delivery of aerosolized liquid. The fluid delivery system includes an injection tip having a set of orifices configured to aerosolize a liquid having certain properties. The injection tip may be couplable with components of a breathing circuit. For example, the injection tip may be couplable with components at or below a wye component (e.g., at a wye component or between the wye component and a patient), such as at the wye component or at an endotracheal tube multi-port connector. Alternatively, the injection tip may be integrated into a breathing circuit, such as at an endotracheal tube connector or at an endotracheal tube.

An electronic inhaling device for detachably receiving a spray bottle having a bottle body with a spray mouth, includes: a casing formed with a vertical slide slot, in which the spray bottle is adapted to be disposed slidably; a bottle support seat installed in the casing, having a receiving inlet permitting extension of the spray mouth of the bottle body when the spray bottle is seated on the support seat and a discharging outlet in spatial communication with the receiving inlet in order to discharge a volatile substance sprayed out from the spray mouth of the bottle body via the discharging outlet; and a monitoring module disposed in the casing for monitoring movement of the spray mouth relative to the bottle body, counting a discharged number of the volatile substance sprayed out from the spray mouth of the bottle body via the discharging outlet.